Company: TVRD
Filing Date: 2025-11-13
Form Type: 424B3
Source: 0001104659-25-111336
Chunk: 0

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 424B3
Chunk 0
---
| PROSPECTUS SUPPLEMENT                  
 (To Prospectus dated November 8, 2025) | Filed Pursuant to Rule 424(b)(3) 
 Registration No. 333-287675      |

<div align='center'>2,084,117 Shares of Common Stock</div>

This prospectus supplement supplements the prospectus dated November 8, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-287675). This prospectus supplement is being filed to update and supplement the information in the Prospectus with certain information contained in our Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 13, 2025 (the “Quarterly Report”). Accordingly, we have attached the Quarterly Report in relevant part to this prospectus supplement.

The Prospectus and this prospectus supplement relates to the resale by certain of the selling stockholders named in the Prospectus (each a “selling stockholder” and, collectively, the “selling stockholders”) of up to 2,084,117 shares of our common stock, par value $0.001 per share (“common stock”) issued to the selling stockholders pursuant to the Agreement and Plan of Merger and Reorganization, dated as of December 17, 2024 (the “Merger Agreement”), by and among Cara Therapeutics, Inc. (“Cara”), CT Convergence Merger Sub, Inc., a wholly owned subsidiary of Cara, and Tvardi Therapeutics, Inc.

Our common stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “TVRD.” On November 12, 2025, the last quoted sale price for our common stock as reported on Nasdaq was $4.24.

This prospectus supplement should be read in conjunction with the Prospectus, including any amendments or supplements thereto, which is to be delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information in this prospectus supplement updates and supersedes the information contained therein.

This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements thereto.

Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in